Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (December 2021)
38 slides from Defence Therapeutics Inc Class A's investor presentation, December 2021
Slide 1: Making a Global Impact
Making a Global Impact | Defence Therapeutics Making A Global Impact Developing Unique Immuno-Oncology Solutions December 2021 CSE: DTC FSE: DTC USOTC: DTCFF 1 Confidential
Slide 2: Corporate Overview
Making a Global Impact | Defence Therapeutics Defence Therapeutics Corporate Overview Uniquely Positioned and Versatile Technology Defence Therapeutics is a Canadian Biotech developing next generation biopharmaceutical innovations for various immuno-oncology (IO) and infectious diseases (ID) indicat
Slide 3: Management and Scientific Team
Making a Global Impact | Defence Therapeutics Management and Scientific Team Sebastien Plouffe, Co-Founder, Dr. Moutih Rafei, VP R&D President and CEO Professor at Université de Montréal Financial expert and entrepreneur with and world renowned expert in 25+ years experience with public Immuno-oncolo
Slide 4: Board Members and Advisors
Making a Global Impact | Defence Therapeutics Board Members and Advisors Sebastien Plouffe, Co-Founder, Dr. Moutih Rafei, VP R&D President and CEO Professor at Université de Montréal Financial expert and entrepreneur with and world renowned expert in 25+ years experience with public Immuno-oncology
Slide 5: Current Challenges: IO and ID
Making a Global Impact | Defence Therapeutics Current Challenges: IO and ID Standard of care currently ineffective against disseminated cancers Targeted biopharmaceuticals struggle with molecular obstacles, limiting their potential to become a therapeutic standard for human diseases (i.e. cancer) No
Slide 6: Global Market for Immuno-Oncology
Making a Global Impact | Defence Therapeutics USD 163.1 Billion Global Market for Immuno-Oncology USD 63.9 Billion Market forecast to grow at CAGR of 14.3% 2020 2027 https://www.reasearchandmarkets.com/reports/5309486 6
Slide 7: Pipeline in Development
Pipeline in Development Making a Global Impact | Defence Therapeutics DISCOVERY PRE-CLINICAL PHASE I - 2022 DC VACCINE INDICATION RESEARCH & DEVELOPMENT NON-GLP GLP Q1 Q2 Q3 Q4 AccuVAC-D001L Lymphoma AccuVAC-D002M Melanoma AccuVAC-D003B Breast IO Program AccuVAC-D004C Colon ADCs AccuADC-001 Breast/G
Slide 8: Accum Technology
Making a Global Impact | Defence Therapeutics Technology Accum molecule eGFP-hGal3-Expressing DCs Bile acid NLS Antigen X • Proprietary platform technology with proven enhanced intracellular delivery • Promotes delivery of target product without 10 non-specific protein/antigen degradation or μm inte
Slide 9: Introducing the DC Vaccine Program
Making a Global Impact | Defence Therapeutics INTRODUCING THE DC VACCINE PROGRAM: Pre-clinical proof of concept AccuVAC-D001L (Lymphoma) AccuVAC-D002M (Melanoma) AccuVAC-D003B (Breast cancer) AccuVAC-D004C (Colon cancer) 9
Slide 10: Sipuleucel-T: The only FDA-approved DC cancer vaccine
Making a Global Impact | Defence Therapeutics Sipuleucel-T: The only FDA-approved DC cancer vaccine 10
Slide 11: The process of developing a DC vaccine
The process of developing a DC vaccine Making a Global Impact | Defence Therapeutics Where the Accum™ formulation is used 11
Slide 12: AccuVAC-D001 leads to potent protection and sustainable memory response
Making a Global Impact | Defence Therapeutics The AccuVAC-D001 Cancer vaccine leads to potent protection and sustainable memory response A 5 x 105 1 x 106 2 x 106 5 10 DCs (SC) EG.7 EG.7 EG.7 Days 0 7 14 21 28 35 42 49 56 63 70 77 84 B C Ctl DC + nOVA DC + aOVA 12
Slide 13: AccuVAC-D001 leads to 70% cure in mice
Therapeutic delivery of the AccuVAC-D001 leads to Making a Global Impact | Defence Therapeutics 70% cure in mice with pre-established tumors A αPD1 (200μg/dose) Days 0 6 12 18 24 3 x 105 DCs (SC) EL4 Lymphoma SC Implantation (5 x 105 cells) B C 4/10 PR 3/10 CR 13
Slide 14: AccuVAC-D001 mechanism of action in the tumor
Making a Global Impact | Defence Therapeutics AccuVAC-D001 mechanism of action in the tumor 1 AccuVAC-D001 Injection 3 Immune cell activation IL-6 αPD- 1 IFNγ CD8 T cells Allo-DC MIP-1β MIP-2 2 Immune cell recruitment 4 Endogenous DC cross-priming NK cells Allogeneic AccuVAC-D001 recruits and activa
Slide 15: Melanoma Phase I trial (UK): 3+3 Design
Making a Global Impact | Defence Therapeutics Melanoma Phase I trial (UK): 3+3 Design Part A Part B AccuVAC-D002M Monotherapy AccuVAC-D002M + anti-PD-1 Dose Escalation 3+3 Design 5 x 106 AccuVAC-D002M 10 x 106 10 x 106 AccuVAC-D002M AccuVAC-D002M 15 x 106 AccuVAC-D002M 15
Slide 16: Introducing the ADC Program
Making a Global Impact | Defence Therapeutics INTRODUCING THE ADC PROGRAM: Pre-clinical proof of concept AccuADC-001 (Breast and gastric cancers) AccuADC-002 (Breast and gastric cancers) 16
Slide 17: What is an Antibody-Drug Conjugate (ADC)?
Making a Global Impact | Defence Therapeutics What is an Antibody-Drug Conjugate (ADC)? Examples: ● Brentuximab (CD30 - HL) ● Trastuzumab (HER2 - Breast cancer) ● Inotuzumab (CD22 - ALL) ● Gemtuzumab (CD33 - AML) Examples: ● maleimidomethyl cyclohexane1-carboxyl Examples: ate (MCC) ● Monomethyl auri
Slide 18: Accum Enhances Therapeutic Potency of Trastuzumab-DM1
Making a Global Impact | Defence Therapeutics Accum™ Enhances Therapeutic Potency of Trastuzumab-DM1 (AccuADC-001) SKBR3 JIMT-1 Accum™ increase potency of % Survival % Survival uncleavable Kadcyla® ADC by 10-100 folds Single ADC injection at 3mg/kg in orthotopic JIMT-1 breast cancer cell in mice T-D
Slide 19: Further Enhancing Our ADC Program
Making a Global Impact | Defence Therapeutics Further Enhancing Ongoing Steps: 8 best Accum™ variants Our ADC program • Defence Therapeutics Inc. has established a collaboration with the HUS Comprehensive Cancer Center in Helsinki, Finland, for the optimization of Defence's Accu-T-DM1 ADC therapeuti
Slide 20: Competitors in the Field
20 Making a Global Impact | Defence Therapeutics Competitors in the Field
Slide 21: Introducing the AccuTOX Program
Making a Global Impact | Defence Therapeutics INTRODUCING THE AccuTOX PROGRAM Pre-clinical proof of concept AccuTOX-001L AccuTOX-002B 21
Slide 22: Enhances antigen uptake when chemically linked
Making a Global Impact | Defence Therapeutics Enhances antigen uptake when chemically linked, but… Resting DCs Activated DCs Accum-Antigen + Resting DCs Cell death Accum + Antigen + 22
Slide 23: AccuTOX-001L as an anti-cancer therapeutic
Making a Global Impact | Defence Therapeutics AccuTOX-001L can be leveraged as an anti-cancer therapeutic with a wide scope of action A B Accum™ molecule 93% EL4 Bile acid NLS 81% CT-26 C Percentage of Live 38% IC50: 95.94 μM (EL4) B16 Death Accum ChA 84% SV40 4T1 Annexin-V Concentration Log[X] 23
Slide 24: Intra-tumoral delivery of AccuTOX-001L delays tumor growth
Making a Global Impact | Defence Therapeutics Intra-tumoral delivery of AccuTOX-001L delays tumor growth as a stand-alone therapy A 5 x 105 EG.7 Accum Days 0 2 4 6 8 10 12 14 16 18 20 22 24 B C A GLP study is currently ongoing 24
Slide 25: Breast Cancer Phase I trial (Canada): 3+3 Design
Making a Global Impact | Defence Therapeutics Breast Cancer Phase I trial (Canada): 3+3 Design Part A Part B AccuVAC-D002M Monotherapy Dose AccuVAC-D002M + T-DM1 Escalation 3+3 Design 0.5 mg/kg AccuTOX-002B 1 mg/kg 1 mg/kg AccuTOX-002B AccuVAC-D002M 5 mg/kg AccuTOX-002B 25
Slide 26: Introducing the COVID (ID) Vaccine Program
Making a Global Impact | Defence Therapeutics INTRODUCING THE COVID (ID) VACCINE PROGRAM: Pre-clinical proof of concept AccuVAC-PT001 AccuVAC-IN002 26
Slide 27: AccuVAC-PT001 induces strong, long-lasting neutralizing humoral responses
Making a Global Impact | Defence Therapeutics A B Sera HEK cells 15 No Adjuvant 12 9 6 Spike 1-pseudotyped Viral particles AccuVAC-PT001 3 Induces strong, 0 long-lasting and 15 AddaSO3TM neutralizing humoral C *** 12 IgG Titer (x106) 5.0 responses 9 * *** ** 4.0 6 NT50 Titers (x104) * ** *** 3 3.0 *
Slide 28: AccuVAC-PT001 antibodies cross-react with all tested variants
Making a Global Impact | Defence Therapeutics AccuVAC-PT001-induced antibodies cross-react with all tested variants California Brazil SA UK India Vietnam 50% 24% 28% 48% 81% 96% AddaSO3TM California Brazil SA UK India Vietnam AddaSVAXTM 49% 23% 21% 47% 53% 96% A challenge study in hamsters is curren
Slide 29: Rabbit non-GLP study for AccuVAC-PT001
Making a Global Impact | Defence Therapeutics Rabbit non-GLP study for AccuVAC-PT001 A B 600 *** Ctl (2x) PRE-IMMUNE T=0 400 (n=3) Week 2 IgG Titer in Sera (x105) Week 4 200 Week 6 *** Dose 1 (n=3) 5 4 3 Dose 2 Very weak 2 (n=3) Titer 1 N.D. 0 Ctl 0.5 μg 5 μg 50 μg FULL NECROPSY Dose 3 Doses (n=3) T
Slide 30: Intranasal delivery of AccuVAC-IN003 triggers mucosal and systemic responses
Making a Global Impact | Defence Therapeutics Intranasal delivery of AccuVAC-IN003 triggers both mucosal and systemic humoral responses B A IN Vaccination (1.0, 2.5 or 5.0 ug/dose) 100000 Saline 1.0 μg/dose *** Bleeding 1000 2.5 μg/dose 5.0 μg/dose ** ** *** 0 1 2 3 4 5 6 Timeline (weeks) IgG Titer
Slide 31: AccuVAC-IN003 induces pro-inflammatory mediators
Making a Global Impact | Defence Therapeutics AccuVAC-IN003 induces a panoply of pro-inflammatory mediators A Ctl 1 μg 2.5 μg 5 μg B Ctl 1 μg 2.5 μg 5 μg G-CSF MCP-1 GM-CSF MIP-1α IFN-γ MIP-1β TNF-α MIP-2 IL-2 RANTES IL-3 IL-5 IL-6 IL-10 IL-17 A GLP study is currently ongoing for IN Vaccination 31
Slide 32: Competitive Technology Advantage in the Field
Making a Global Impact | Defence Therapeutics Competitive Technology DTC”s RNA DNA Viral advantage in Platforms AccuVac-IN003 Vectors Expected No. the Field of doses 1 to 2 2 to 3 2 1 to 2 Route of Intransal Injection + Injection Injection Administration spray Electroporation Mucosal Immunity Yes No
Slide 33: Introducing the HPV Vaccine Program
Making a Global Impact | Defence Therapeutics INTRODUCING THE HPV VACCINE PROGRAM: Discovery Stage AccuVAC-PT004 33
Slide 34: Current HPV vaccines are great, but not perfect
Making a Global Impact | Defence Therapeutics Current HPV vaccines are great, but not perfect! - According to the CDC, the HPV vaccination decreased rates of infection with HPV in half in American teenagers (from 11.5% to 4.3%) and by one third in American women in their early twenties (from 18.5% t
Slide 35: Our Proposed Strategy
Making a Global Impact | Defence Therapeutics Our Proposed Strategy Current Strategy Defence Strategy L1 Proteins HPV 6 A mix of chemically-linked L1 proteins to Accum HPV 11 HPV 16 HPV 18 HPV 31 HPV 33 HPV 45 HPV 52 HPV 58 35
Slide 36: Competitors in the Field
Making a Global Impact | Defence Therapeutics Competitors in the Field Prophylactic Vaccination Therapeutic Vaccination GARDASIL VGX-3100 CERVARIX GARDASIL 9 (DNA Vaccine in Phase III) 36
Slide 37: Overall Summary
Making a Global Impact | Defence Therapeutics Overall Summary Accum™ molecule Bile acid NLS Highly Versatile Technology Enhance significantly the Augment the anti-tumoral Easily applicable to ID Development of novel small therapeutic potency of DC potency of FDA-approved protein-based vaccines molec
Slide 38: Thank You
Making a Global Impact | Defence Therapeutics Thank You (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com 1680 - 200 Burrard Street, Vancouver, BC, V6C 3L6 Confidential 38
Defence Therapeutics — Investor Presentation (December 2021) on 6ix